Travere Therapeutics (TVTX) Tops Q4 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
February 23, 2023 4:01 PM ESTRecently received U.S. FDA accelerated approval of FILSPARI (sparsentan), the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy (IgAN)
European Medicines Agency (EMA) review decision for potential conditional approval of sparsentan in IgAN anticipated in second half of 2023
Pivotal DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS)Â on track to report topline data from confirmatory two-year endpoints in second quarter of 2023
Net product sales of $52 million for the fourth quarter of 2022; $201 million for the full year... More
